<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250207</date><key>collection.key</key><document><id>PMC8695896</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.3389/fonc.2021.796774</infon><infon key="article-id_pmc">PMC8695896</infon><infon key="article-id_pmid">34956908</infon><infon key="elocation-id">796774</infon><infon key="kwd">MEG3 polymorphism rs7158663 cancer susceptibility</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</infon><infon key="name_0">surname:Gao;given-names:Xueren</infon><infon key="name_1">surname:Li;given-names:Xianyang</infon><infon key="name_2">surname:Zhang;given-names:Shulong</infon><infon key="name_3">surname:Wang;given-names:Xiaoting</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">11</infon><infon key="year">2021</infon><offset>0</offset><text>The Association of MEG3 Gene rs7158663 Polymorphism With Cancer Susceptibility</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>79</offset><text>Although the association of MEG3 gene rs7158663 polymorphism with cancer susceptibility has been investigated, the findings are inconsistent. The aim of this study was to analyze the association between the rs7158663 polymorphism and cancer susceptibility through a case-control study and meta-analysis. In a case-control study with 430 colorectal cancer (CRC) cases and 445 healthy controls, the rs7158663 polymorphism was genotyped by direct sequencing. STATA software was used to calculate the pooled odds ratio and 95% confidence interval in a meta-analysis including 4,649 cancer cases and 5,590 controls. Both the case-control study and meta-analysis showed that the rs7158663 polymorphism was associated with increased susceptibility to CRC. Individuals carrying the AA or GA genotype were more likely to develop CRC than those carrying the rs7158663 GG genotype. Interestingly, MEG3 expression was significantly lower in colorectal tissues of the AA or GA genotype compared to those of the rs7158663 GG genotype. In addition, the meta-analysis suggested that the rs7158663 polymorphism was also associated with increased susceptibility to breast cancer and gastric cancer. Bioinformatics analysis showed that the rs7158663 A allele contributed to the binding of hsa-miR-4307 and hsa-miR-1265 to MEG3. In conclusion, the current findings suggest that the MEG3 gene rs7158663 polymorphism may serve as a genetic marker for predicting the risk of cancers, such as breast cancer, gastric cancer and CRC. However, the sample size of the current study is still insufficient, especially in the subgroup analysis. Therefore large and well-designed studies are needed to validate our findings.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1772</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1785</offset><text>Cancer is one of the most serious public health issues in the world, with approximately 18.1 million new cancer diagnoses and 9.6 million cancer deaths in 2018. Although the precise processes of cancer development and progression are still largely unclear, a growing body of research suggests that genetic predisposition has a substantial influence on the likelihood of individual cancer development.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2186</offset><text>Long non-coding RNA (lncRNA) is a form of RNA transcript that is longer than 200 nucleotides but does not transcribe into protein in cells. LncRNAs play a role in a variety of cell activities, such as cell proliferation, migration, invasion, and angiogenesis, and their dysregulation has been linked to a variety of cancers. Maternally expressed 3 (MEG3) is one of the most well-studied lncRNAs and is expressed in multiple organs, such as the liver, brain, pancreas, stomach and ovary. However, MEG3 expression is typically suppressed in a variety of cancer tissues. Functional studies showed that this lncRNA could regulate the expression of various tumor suppressor genes and oncogenes. Zhu et al. found that ectopic expression of MEG3 could significantly inhibit proliferation and induce apoptosis in hepatoma cells. MEG3 could function as a tumor suppressor in hepatoma cells through interacting with p53 protein to activate p53-mediated transcriptional activity and influence the expression of partial p53 target genes. Dong et al. found that downregulation of MEG3 expression could promote proliferation, migration, and invasion of hepatocellular carcinoma cells by upregulating TGF-beta1 expression. Zuo et al. demonstrated that MEG3 activated by vitamin D could inhibit glycolysis in colorectal cancer (CRC) via promoting c-Myc degradation. Xu et al. found that MEG3 could mediate the miR-149-3p/FOXP3 axis by reducing p53 ubiquitination to exert a suppressive effect on regulatory T cell differentiation and immune escape in esophageal cancer. In addition, certain polymorphisms (rs3087918 T&gt;G, rs11160608 A&gt;C, rs4081134 G&gt;A, rs7158663 A&gt;G) within the MEG3 gene are implicated in cancer susceptibility. For example, MEG3 gene rs3087918 was associated with a decreased risk of breast cancer in a Chinese population. MEG3 gene rs11160608 was related to an increased risk of oral squamous cell carcinoma in a Chinese Han population. MEG3 gene rs4081134 was significantly associated with a decreased risk of lung cancer in a Northeast Chinese population. MEG3 gene rs7158663 is the most interesting polymorphic locus located on the MEG3 transcript. Bioinformatic analysis showed that the rs7158663 polymorphism had the potential to change the local RNA folding structure and affect miRNA-lncRNA interactions, which in turn affected the expression level of miRNA and/or MEG3. Several studies have explored the relationship between this potentially functional polymorphism and cancer susceptibility, but the results are inconsistent and need to be further clarified.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4760</offset><text>In the current study, we first explored the relationship between the rs7158663 polymorphism and CRC susceptibility using a case-control study, and then analyzed its effect on MEG3 expression in colorectal tissues. In addition, a meta-analysis was conducted to systematically evaluated the relationship between this polymorphism and cancer susceptibility, which would help us to better understand the role of the rs7158663 polymorphism in cancer susceptibility.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5221</offset><text>Materials And Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5243</offset><text>Sample Collection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5262</offset><text>Peripheral blood of 430 CRC patients and 445 healthy controls were collected from Shanghai Xuhui District Central Hospital. All participants were genetically unrelated Han Chinese. Diagnosis of CRC patients was histopathologically confirmed. Healthy controls were cancer-free individuals living in the same residential area and seeking routine physical exams. Furthermore, colorectal tissues were obtained from 40 CRC surgery patients who had not received radiochemotherapy before surgery. Written informed consent was obtained from all participants. The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Shanghai Xuhui District Central Hospital.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6012</offset><text>Genotyping</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6023</offset><text>TIANamp genomic DNA Kit (Tiangen) was used to isolate genomic DNA from peripheral blood according to the manufacturer's instructions. Genomic DNA concentration was detected using a NanoDrop spectrophotometer. Direct sequencing was used to detect the genotype of the rs7158663 locus in each individual.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6327</offset><text>Real-Time Quantitative PCR</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6354</offset><text>Total RNA was isolated from colorectal tissues using the RNAsimple total RNA kit (Tiangen) according to the manufacturer's instructions. ReverTra Ace qPCR RT Kit (TOYOBO) was used to synthesize cDNA. FastStart Universal SYBR Green Master (Roche) was used to conduct real-time quantitative PCR. MEG3 expression was normalized to the internal control GAPDH. The specific primer sequences are presented in  Table S1 .</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6771</offset><text>Bioinformatic Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6794</offset><text>The lncRNASNP online tool () was used to analyze whether the rs7158663 polymorphism affects miRNA binding.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6901</offset><text>Statistical Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6922</offset><text>Hardy-Weinberg equilibrium (HWE) for the control group was tested by a goodness-of-fit chi2 test. The association of MEG3 gene rs7158663 polymorphism with CRC susceptibility was evaluated using adjusted odds ratios (ORs) with their 95% confidence intervals (CIs). Student's t-test was used to check the differences for age variable between CRC cases and controls. chi2 test was used to assess the differences in gender variable between CRC cases and controls. The normalized expression levels of MEG3 among different genotypes were compared using one-way ANOVA. All statistical analyses were performed by SAS 9.4 (SAS Institute, Cary, USA). P &lt; 0.05 was defined as the level of significance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7614</offset><text>Meta-Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7628</offset><text>PubMed, CNKI and EMBASE databases were searched based on the following keywords: &quot;Maternally expressed 3 or MEG3&quot;, &quot;polymorphism or variant&quot; and &quot;cancer or carcinoma or malignancy&quot;. The last literature search was conducted on October 7, 2021. The primary inclusion criterion for previous studies was to have sufficient genotype data. If numerous studies had overlapping or duplicate data, only studies with complete data were included. Data from the included studies were extracted independently by two investigators. Disagreements were settled by conversation. The pooled ORs and their 95% CIs were applied to determine the relationship of the rs7158663 polymorphism with cancer susceptibility. The between-study heterogeneity was assessed using Chi-square-based statistic I2 test and Cochran's Q-test. When I2 &gt; 50% or PH &lt; 0.1, we used the random-effects model to estimate the pooled OR. Otherwise, the fixed-effects model was applied. To assess the quality and consistency of the results, sensitivity analysis was undertaken by removing each study in turn. Begg's and Egger's tests were used to assess potential publication bias. Trial sequential analysis (TSA) was conducted in a selected genetic model to assess the statistical reliability of the meta-analysis. TSA was conducted with a 5% risk of type I error and a 20% risk of type II error. The statistical analyses were performed by STATA 12.0 (Stata Corporation, College Station, TX, USA).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>9097</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>9105</offset><text>The results of the case-control study are shown in  Table 1 . There was no statistical difference in the age and gender distribution between the case and control groups (P&gt;0.05). The genotype frequency distribution of the control group was consistent with HWE (PHWE=0.43). There was a significant association between MEG3 gene rs7158663 polymorphism and CRC susceptibility [GA vs. GG: OR=1.48, 95%CI= 1.11-1.96, P=0.007; AA vs. GG: OR=1.83, 95%CI=1.11-3.03, P=0.018; (GA+AA) vs. GG: OR=1.53, 95%CI=1.17-2.00, P=0.002; A vs. G: OR=1.41, 95%CI=1.14-1.74, P=0.001].</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>9669</offset><text>Characteristics of age, gender and rs7158663 polymorphism in cases and controls.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Variables&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case (%) (N = 430)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Controls (%) (N = 445)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;xref rid=&quot;fnT1_1&quot; ref-type=&quot;table-fn&quot;&gt;
&lt;sup&gt;a&lt;/sup&gt;
&lt;/xref&gt;OR (95% CI)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;xref rid=&quot;fnT1_1&quot; ref-type=&quot;table-fn&quot;&gt;
&lt;sup&gt;a&lt;/sup&gt;
&lt;/xref&gt;P value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age, mean +- SD&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57.7 +- 5.9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57.7 +- 6.1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.86&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gender&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;251 (58.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;249 (56.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.47&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Female&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;179 (41.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;196 (44.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Genotype&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;202 (47.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;256 (57.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; GA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;185 (43.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;159 (35.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.48 (1.11-1.96)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.007&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; AA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43 (10.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (6.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.83 (1.11-3.03)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.018&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;P&lt;sub&gt;trend&lt;/sub&gt;
&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;P&lt;sub&gt;HWE&lt;/sub&gt;
&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.43&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;202 (47.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;256 (57.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; GA+AA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;228 (53.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;189 (42.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.53 (1.17-2.00)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; GG+GA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;387 (90.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;415 (93.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43 (10.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (6.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.55 (0.95-2.52)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.08&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Allele&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; G&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;589 (68.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;671 (75.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; A&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;271 (31.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;219 (24.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.41 (1.14-1.74)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>9750</offset><text>Variables	Case (%) (N = 430)	Controls (%) (N = 445)	aOR (95% CI)	aP value	 	Age, mean +- SD	57.7 +- 5.9	57.7 +- 6.1		0.86	 	Gender					 	Male	251 (58.4)	249 (56.0)		0.47	 	Female	179 (41.6)	196 (44.0)			 	Genotype					 	 GG	202 (47.0)	256 (57.5)	Reference		 	 GA	185 (43.0)	159 (35.7)	1.48 (1.11-1.96)	0.007	 	 AA	43 (10.0)	30 (6.7)	1.83 (1.11-3.03)	0.018	 	Ptrend				0.002	 	PHWE				0.43	 	 GG	202 (47.0)	256 (57.5)	Reference		 	 GA+AA	228 (53.0)	189 (42.5)	1.53 (1.17-2.00)	0.002	 	 GG+GA	387 (90.0)	415 (93.3)	Reference		 	AA	43 (10.0)	30 (6.7)	1.55 (0.95-2.52)	0.08	 	Allele					 	 G	589 (68.5)	671 (75.4)	Reference		 	 A	271 (31.5)	219 (24.6)	1.41 (1.14-1.74)	0.001	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>10440</offset><text>Adjusted for age and gender when appropriate.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10486</offset><text>Genotype-tissue expression results showed that the rs7158663 polymorphism was significantly associated with the expression of MEG3 in colorectal tissues. MEG3 expression was significantly lower in colorectal tissues of the AA or GA genotype compared to those of the rs7158663 GG genotype ( Figure 1 ). The results of bioinformatics analysis showed that the rs7158663 A allele contributed to the binding of hsa-miR-4307 and hsa-miR-1265 to MEG3 ( Figure 2 ).</text></passage><passage><infon key="file">fonc-11-796774-g001.jpg</infon><infon key="id">f1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>10946</offset><text>Relationship between rs7158663 genotype and MEG3 expression in CRC tissues (A) and normal paracancerous tissues (B). ***p &lt; 0.001.</text></passage><passage><infon key="file">fonc-11-796774-g002.jpg</infon><infon key="id">f2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11077</offset><text>lncRNASNP-based analysis of the effect of rs7158663 polymorphism on miRNA binding.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11160</offset><text>Based on database searches, a total of 11 case-control studies exploring the association of the rs7158663 polymorphism with cancer susceptibility were included in the current meta-analysis ( Figure S1 ). The relevant studies were published between 2016 and 2021. The current meta-analysis combined our results included 4,649 cancer cases and 5,590 controls ( Table 2 ). The overall combined analysis showed that the rs7158663 polymorphism was not associated with cancer susceptibility ( Table 3 ). However, the country-based stratified analysis showed that the rs7158663 polymorphism was associated with cancer susceptibility in the Chinese population under (AA+AG) vs. GG, AA vs. (AG+GG), AA vs. GG, AG vs. GG, and A vs. G models, and in the Egyptians under (AA+AG) vs. GG model. The stratified analysis based on cancer type showed that the rs7158663 polymorphism was associated with susceptibility to breast cancer under (AA+AG) vs. GG and AG vs. GG models, and gastric cancer under (AA+AG) vs. GG, AA vs. (AG+GG), AA vs. GG, AG vs. GG, and A vs. G models, and colorectal cancer under (AA+AG) vs. GG, AA vs. (AG+GG), AA vs. GG, AG vs. GG, and A vs. G models.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>12323</offset><text>Main characteristics of the case-control studies in the current meta-analysis.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;left&quot; colspan=&quot;1&quot;&gt;Authors &lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;Year of publication&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;Country&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;Cancer type&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;Genotyping method&lt;/th&gt;&lt;th valign=&quot;top&quot; colspan=&quot;4&quot; align=&quot;center&quot; rowspan=&quot;1&quot;&gt;Number of cases&lt;/th&gt;&lt;th valign=&quot;top&quot; colspan=&quot;4&quot; align=&quot;center&quot; rowspan=&quot;1&quot;&gt;Number of controls&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;P&lt;sub&gt;HWE&lt;/sub&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GG&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GA&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Total&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GG&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GA&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Total&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gao et al.&lt;sup&gt;*&lt;/sup&gt;
&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2021&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;202&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;185&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;430&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;256&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;159&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;445&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.43&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shaker et al. &lt;xref rid=&quot;B21&quot; ref-type=&quot;bibr&quot;&gt;21&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2021&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Egypt&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63&lt;/td&gt;&lt;td valign=&quot;top&quot; colspan=&quot;2&quot; align=&quot;center&quot; rowspan=&quot;1&quot;&gt;117&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;180&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93&lt;/td&gt;&lt;td valign=&quot;top&quot; colspan=&quot;2&quot; align=&quot;center&quot; rowspan=&quot;1&quot;&gt;57&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Kong et al. &lt;xref rid=&quot;B22&quot; ref-type=&quot;bibr&quot;&gt;22&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;215&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;198&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;61&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;474&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;290&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;203&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;543&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Xu et al. &lt;xref rid=&quot;B23&quot; ref-type=&quot;bibr&quot;&gt;23&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prostate cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;98&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;165&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;111&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;200&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.57&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zheng et al. &lt;xref rid=&quot;B14&quot; ref-type=&quot;bibr&quot;&gt;14&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MassArray&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;224&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;170&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;427&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;403&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;250&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;700&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.33&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ali et al. &lt;xref rid=&quot;B24&quot; ref-type=&quot;bibr&quot;&gt;24&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Egypt&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;84&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;154&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mazraeh et al. &lt;xref rid=&quot;B25&quot; ref-type=&quot;bibr&quot;&gt;25&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Iran&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Acute myeloid leukemia&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PCR-based restriction fragment length&lt;break/&gt;polymorphism&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;100&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;100&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wei &lt;xref rid=&quot;B26&quot; ref-type=&quot;bibr&quot;&gt;26&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2019&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Liver cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Taqman&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;717&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;349&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1117&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;795&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;391&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;62&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1248&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yang et al. &lt;xref rid=&quot;B16&quot; ref-type=&quot;bibr&quot;&gt;16&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2018&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lung cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Taqman&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;268&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;219&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;526&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;289&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;204&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;526&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.71&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhuo et al. &lt;xref rid=&quot;B27&quot; ref-type=&quot;bibr&quot;&gt;27&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2018&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neuroblastoma&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;233&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;141&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;392&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;433&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;296&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;783&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.72&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhang et al. &lt;xref rid=&quot;B28&quot; ref-type=&quot;bibr&quot;&gt;28&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2018&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;83&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;74&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;172&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;138&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;224&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.91&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cao et al. &lt;xref rid=&quot;B29&quot; ref-type=&quot;bibr&quot;&gt;29&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2016&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TaqMan&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;264&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;200&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;52&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;516&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;298&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;188&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;517&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.85&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>12402</offset><text>Authors 	Year of publication	Country	Cancer type	Genotyping method	Number of cases	Number of controls	PHWE	 	GG	GA	AA	Total	GG	GA	AA	Total	 	Gao et al.*	2021	China	Colorectal cancer	TaqMan	202	185	43	430	256	159	30	445	0.43	 	Shaker et al. 	2021	Egypt	Breast cancer	TaqMan	63	117	180	93	57	150	-	 	Kong et al. 	2020	China	Gastric cancer	TaqMan	215	198	61	474	290	203	50	543	0.1	 	Xu et al. 	2020	China	Prostate cancer	TaqMan	98	54	13	165	111	78	11	200	0.57	 	Zheng et al. 	2020	China	Breast cancer	MassArray	224	170	33	427	403	250	47	700	0.33	 	Ali et al. 	2020	Egypt	Breast cancer	TaqMan	57	63	30	150	84	63	7	154	0.26	 	Mazraeh et al. 	2020	Iran	Acute myeloid leukemia	PCR-based restriction fragment lengthpolymorphism	43	36	21	100	16	48	36	100	1	 	Wei 	2019	China	Liver cancer	Taqman	717	349	51	1117	795	391	62	1248	0.13	 	Yang et al. 	2018	China	Lung cancer	Taqman	268	219	39	526	289	204	33	526	0.71	 	Zhuo et al. 	2018	China	Neuroblastoma	TaqMan	233	141	18	392	433	296	54	783	0.72	 	Zhang et al. 	2018	China	Gastric cancer	TaqMan	83	74	15	172	138	76	10	224	0.91	 	Cao et al. 	2016	China	Colorectal cancer	TaqMan	264	200	52	516	298	188	31	517	0.85	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>13569</offset><text>
*Current study.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>13586</offset><text>Meta-analysis of the association between the rs7158663 polymorphism and cancer risk.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;left&quot; colspan=&quot;1&quot;&gt;Comparison&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;
&lt;sup&gt;*&lt;/sup&gt;Subgroup&lt;/th&gt;&lt;th valign=&quot;top&quot; colspan=&quot;2&quot; align=&quot;center&quot; rowspan=&quot;1&quot;&gt;Heterogeneity&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;Effect model&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;OR[95%CI]&lt;/th&gt;&lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;P&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;P&lt;sub&gt;H&lt;/sub&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;I&lt;sup&gt;2&lt;/sup&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(AA+AG) vs. GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Overall&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.00001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;83%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.22[0.99,1.49]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.06&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.003&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.18[1.02,1.37]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.03&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Egypt&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.18&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.44[1.77,3.37]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.00001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;85%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.89[1.08,3.30]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.36&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.47[1.19,1.81]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0004&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.38&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.40[1.17,1.68]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA vs. (AG+GG)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Overall&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0003&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.27[0.95,1.70]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.11&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.11&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.23[1.05,1.44]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.002&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;89%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.36[0.54,10.42]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.26&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.47&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.55[1.09,2.22]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.65[1.18,2.31]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA vs. GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Overall&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.00001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;80%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.31[0.90,1.90]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.16&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.02&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.33[1.03,1.73]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.03&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.002&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;90%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.70[0.55,13.13]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.22&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.39&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.78[1.23,2.58]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.91&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.86[1.32,2.62]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0004&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AG vs. GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Overall&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0004&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.11[0.94,1.31]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.21&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.04&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.15[1.01,1.31]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.51&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.27[1.02,1.60]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.41&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.39[1.12,1.74]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.29&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.32[1.09,1.60]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.004&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;A vs. G&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Overall&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.00001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;84%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.14[0.96,1.34]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0007&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.16[1.02,1.32]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.004&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;88%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Random&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.53[0.87,2.69]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.14&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gastric cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.32&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.38[1.17,1.63]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colorectal cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.61&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0%&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fixed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.36[1.17,1.56]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.0001&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13671</offset><text>Comparison	*Subgroup	Heterogeneity	Effect model	OR[95%CI]	P	 	PH	I2	 	(AA+AG) vs. GG	Overall	&lt;0.00001	83%	Random	1.22[0.99,1.49]	0.06	 		China	0.003	65%	Random	1.18[1.02,1.37]	0.03	 		Egypt	0.18	44%	Fixed	2.44[1.77,3.37]	&lt;0.00001	 		Breast cancer	0.001	85%	Random	1.89[1.08,3.30]	0.02	 		Gastric cancer	0.36	0%	Fixed	1.47[1.19,1.81]	0.0004	 		Colorectal cancer	0.38	0%	Fixed	1.40[1.17,1.68]	0.0003	 	AA vs. (AG+GG)	Overall	0.0003	70%	Random	1.27[0.95,1.70]	0.11	 		China	0.11	39%	Fixed	1.23[1.05,1.44]	0.01	 		Breast cancer	0.002	89%	Random	2.36[0.54,10.42]	0.26	 		Gastric cancer	0.47	0%	Fixed	1.55[1.09,2.22]	0.02	 		Colorectal cancer	0.7	0%	Fixed	1.65[1.18,2.31]	0.003	 	AA vs. GG	Overall	&lt;0.00001	80%	Random	1.31[0.90,1.90]	0.16	 		China	0.02	55%	Random	1.33[1.03,1.73]	0.03	 		Breast cancer	0.002	90%	Random	2.70[0.55,13.13]	0.22	 		Gastric cancer	0.39	0%	Fixed	1.78[1.23,2.58]	0.002	 		Colorectal cancer	0.91	0%	Fixed	1.86[1.32,2.62]	0.0004	 	AG vs. GG	Overall	0.0004	69%	Random	1.11[0.94,1.31]	0.21	 		China	0.04	51%	Random	1.15[1.01,1.31]	0.04	 		Breast cancer	0.51	0%	Fixed	1.27[1.02,1.60]	0.04	 		Gastric cancer	0.41	0%	Fixed	1.39[1.12,1.74]	0.003	 		Colorectal cancer	0.29	10%	Fixed	1.32[1.09,1.60]	0.004	 	A vs. G	Overall	&lt;0.00001	84%	Random	1.14[0.96,1.34]	0.14	 		China	0.0007	70%	Random	1.16[1.02,1.32]	0.02	 		Breast cancer	0.004	88%	Random	1.53[0.87,2.69]	0.14	 		Gastric cancer	0.32	0%	Fixed	1.38[1.17,1.63]	0.0001	 		Colorectal cancer	0.61	0%	Fixed	1.36[1.17,1.56]	&lt;0.0001	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>15166</offset><text>

*
Two and more studies were combined for analysis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15219</offset><text>The sensitivity analysis showed that after Mazraeh's study was removed, the overall combined results were significantly altered under all comparison models ( Figure S2 ). After Zhuo's study was removed, the overall combined results were significantly altered under (AA+AG) vs. GG, and AA vs. (AG+GG) models. After Xu's study was removed, the overall combined results were significantly altered under (AA+AG) vs. GG model. Begg's and Egger's tests showed no publication bias in the current meta-analysis ( Table 4 ). TSA was conducted in the (AA+AG) vs. GG model. The result showed that the cumulative Z-curve (blue line) has crossed the required information sizes (n=8,329) ( Figure 3 ), which indicated that the cumulative evidence was adequate in the overall analysis.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>16002</offset><text>Publication bias analysis of included studies.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Comparison&lt;/th&gt;&lt;th valign=&quot;top&quot; colspan=&quot;2&quot; align=&quot;center&quot; rowspan=&quot;1&quot;&gt;P value&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Begg's test&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Egger's test&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(AA+AG) vs. GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA vs. (AG+GG)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.53&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.57&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AA vs. GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.64&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.39&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AG vs. GG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.76&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.60&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;A vs. G&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.64&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.39&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>16049</offset><text>Comparison	P value	 		Begg's test	Egger's test	 	(AA+AG) vs. GG	1	0.58	 	AA vs. (AG+GG)	0.53	0.57	 	AA vs. GG	0.64	0.39	 	AG vs. GG	0.76	0.60	 	A vs. G	0.64	0.39	 	</text></passage><passage><infon key="file">fonc-11-796774-g003.jpg</infon><infon key="id">f3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>16218</offset><text>Trial sequential analysis of the current meta-analysis under the (AA+AG) vs. GG model.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>16305</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16316</offset><text>Recent studies have shown that certain genetic variants on lncRNA genes may be associated with cancer risk. These genetic variants contain the rs7158663 polymorphism on the MEG3 gene. For instance, Cao et al. found that rs7158663 AA genotype had significantly higher CRC risk than GG genotype, which was consistent with our results. The further stratified analysis revealed that the elevated risk was strongly associated with people with age &lt;= 60 and a family history of cancer. However, there was no link found between the rs7158663 polymorphism and CRC site or stage. Both Zhang et al. and Kong et al. found that individuals carrying the rs7158663 AG+AA genotype or A allele had a significantly increased risk of gastric cancer. However, some studies suggested that the rs7158663 polymorphism was not associated with cancer risk. For instance, Wei found that the rs7158663 polymorphism was not associated with hepatocarcinogenesis. Yang et al. found that the rs7158663 polymorphism was not associated with susceptibility to lung cancer. Zhuo et al. found that the rs7158663 polymorphism was not linked with neuroblastoma susceptibility, regardless of whether it was corrected for age and gender. These inconsistent results forced us to clarify the relationship between the rs7158663 polymorphism and cancer susceptibility by meta-analysis. By combining two and more studies for analysis, we found that the rs7158663 polymorphism was not associated with overall cancer susceptibility. However, the country-based stratified analysis showed that the rs7158663 polymorphism was associated with cancer susceptibility in the Chinese population under (AA+AG) vs. GG, AA vs. (AG+GG), AA vs. GG, AG vs. GG, and A vs. G models, and in the Egyptians under (AA+AG) vs. GG model. The stratified analysis based on cancer type showed that the rs7158663 polymorphism was associated with susceptibility to breast cancer under (AA+AG) vs. GG and AG vs. GG models, and gastric cancer under (AA+AG) vs. GG, AA vs. (AG+GG), AA vs. GG, AG vs. GG, and A vs. G models, and colorectal cancer under (AA+AG) vs. GG, AA vs. (AG+GG), AA vs. GG, AG vs. GG, and A vs. G models. There was no publication bias in the current meta-analysis, and TSA suggested that the sample size in the overall combined analysis was adequate. However, the sensitivity analysis results suggested that the current meta-analysis results were not sufficiently stable. Therefore we needed more studies to confirm the current findings.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18805</offset><text>MEG3 could inhibit the malignant phenotype of many cancers including gastric, breast and colorectal cancers. The current study found that the rs7158663 polymorphism could affect MEG3 expression in colorectal tissues. MEG3 expression was significantly lower in colorectal tissues of the AA or GA genotype compared to those of the rs7158663 GG genotype. Bioinformatics analysis showed that the rs7158663 A allele contributed to the binding of hsa-miR-4307 and hsa-miR-1265 to MEG3. Therefore, we speculated that the rs7158663 polymorphism may affect an individual's susceptibility to CRC by influencing the regulation of MEG3 expression by miRNAs.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19453</offset><text>Although the current study has yielded some meaningful results, some shortcomings needed to be pointed out. Due to the insufficient sample size of the current case-control study and the unavailability of some clinical data, we did not further analyze the relationship between the rs7158663 polymorphism and the clinicopathological features. In addition, we did not consider the effect of the rs7158663 polymorphism interaction with environmental factors on cancer susceptibility.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>19933</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19945</offset><text>The current study results suggest that the MEG3 gene rs7158663 polymorphism is associated with susceptibility to a variety of cancers, such as breast cancer, gastric cancer and CRC. However, large and well-designed studies are still needed to validate our findings.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>20211</offset><text>Data Availability Statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>20239</offset><text>The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding author.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>20406</offset><text>Ethics Statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>20423</offset><text>The studies involving human participants were reviewed and approved by Shanghai Xuhui District Central Hospital. The patients/participants provided their written informed consent to participate in this study.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>20632</offset><text>Author Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>20653</offset><text>XG carried out the molecular genetic studies, did the literature search and the statistical analysis, and wrote the paper. XL performed biochemistry tests. XW were responsible for the acquisition of data. SZ participated in study design and coordination and helped to draft the manuscript. XG and SZ interpreted the data and were responsible for the manuscript preparation. All authors contributed to the article and approved the submitted version.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>21102</offset><text>Conflict of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>21123</offset><text>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>21296</offset><text>Publisher's Note</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>21315</offset><text>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>21662</offset><text>Supplementary Material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>21685</offset><text>The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.796774/full#supplementary-material </text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>21844</offset><text>References</text></passage><passage><infon key="fpage">394</infon><infon key="issue">6</infon><infon key="lpage">424</infon><infon key="name_0">surname:Bray;given-names:F</infon><infon key="name_1">surname:Ferlay;given-names:J</infon><infon key="name_2">surname:Soerjomataram;given-names:I</infon><infon key="name_3">surname:Siegel;given-names:RL</infon><infon key="name_4">surname:Torre;given-names:LA</infon><infon key="name_5">surname:Jemal;given-names:A</infon><infon key="pub-id_doi">10.3322/caac.21492</infon><infon key="pub-id_pmid">30207593</infon><infon key="section_type">REF</infon><infon key="source">CA Cancer J Clin</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2018</infon><offset>21855</offset><text>Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</text></passage><passage><infon key="issue">8</infon><infon key="name_0">surname:Gao;given-names:X</infon><infon key="name_1">surname:Wang;given-names:X</infon><infon key="pub-id_doi">10.1080/15257770.2021.1952596</infon><infon key="section_type">REF</infon><infon key="source">Nucleosides Nucleotides Nucleic Acids</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2021</infon><offset>21974</offset><text>HMGA2 Rs968697 T &gt; C Polymorphism Is Associated With the Risk of Colorectal Cancer</text></passage><passage><infon key="fpage">300060520941969</infon><infon key="name_0">surname:Ni;given-names:W</infon><infon key="name_1">surname:Wang;given-names:X</infon><infon key="name_2">surname:Sun;given-names:Y</infon><infon key="name_3">surname:Gao;given-names:X</infon><infon key="pub-id_doi">10.1177/0300060520941969</infon><infon key="pub-id_pmid">32720826</infon><infon key="section_type">REF</infon><infon key="source">J Int Med Res</infon><infon key="type">ref</infon><infon key="volume">48</infon><infon key="year">2020</infon><offset>22061</offset><text>Meta-Analysis of the Association Between MALAT1 Rs619586 a&gt;G Polymorphism and Cancer Risk</text></passage><passage><infon key="fpage">1683129</infon><infon key="name_0">surname:Qi;given-names:ZY</infon><infon key="name_1">surname:Wang;given-names:LL</infon><infon key="name_2">surname:Qu;given-names:XL</infon><infon key="pub-id_doi">10.1155/2021/1683129</infon><infon key="pub-id_pmid">34603558</infon><infon key="section_type">REF</infon><infon key="source">Dis Markers</infon><infon key="type">ref</infon><infon key="volume">2021</infon><infon key="year">2021</infon><offset>22151</offset><text>lncRNA LINC00355 Acts as a Novel Biomarker and Promotes Glioma Biological Activities via the Regulation of miR-1225/FNDC3B</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Feng;given-names:Y</infon><infon key="name_1">surname:Wei;given-names:G</infon><infon key="name_2">surname:Zhang;given-names:L</infon><infon key="name_3">surname:Zhou;given-names:H</infon><infon key="name_4">surname:Wang;given-names:W</infon><infon key="name_5">surname:Guo;given-names:P</infon><infon key="pub-id_doi">10.1080/21655979.2021.1982272</infon><infon key="section_type">REF</infon><infon key="source">Bioengineered</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2021</infon><offset>22274</offset><text>LncRNA DARS-AS1 Aggravates the Growth and Metastasis of Hepatocellular Carcinoma via Regulating the miR-3200-5p-Cytoskeleton Associated Protein 2 (CKAP2) Axis</text></passage><passage><infon key="fpage">112855</infon><infon key="issue">1</infon><infon key="name_0">surname:Fu;given-names:C</infon><infon key="name_1">surname:Xin;given-names:J</infon><infon key="name_2">surname:Zhang;given-names:W</infon><infon key="name_3">surname:Lai;given-names:J</infon><infon key="name_4">surname:Huang;given-names:Z</infon><infon key="pub-id_doi">10.1016/j.yexcr.2021.112855</infon><infon key="pub-id_pmid">34599930</infon><infon key="section_type">REF</infon><infon key="source">Exp Cell Res</infon><infon key="type">ref</infon><infon key="volume">408</infon><infon key="year">2021</infon><offset>22433</offset><text>LINC00992 Exerts Oncogenic Activities in Prostate Cancer via Regulation of SOX4</text></passage><passage><infon key="fpage">101644</infon><infon key="name_0">surname:Xu;given-names:L</infon><infon key="name_1">surname:Liu;given-names:C</infon><infon key="name_2">surname:Ye;given-names:Z</infon><infon key="name_3">surname:Wu;given-names:C</infon><infon key="name_4">surname:Ding;given-names:Y</infon><infon key="name_5">surname:Huang;given-names:J</infon><infon key="pub-id_doi">10.1016/j.tice.2021.101644</infon><infon key="pub-id_pmid">34555778</infon><infon key="section_type">REF</infon><infon key="source">Tissue Cell</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">2021</infon><offset>22513</offset><text>Overexpressed LINC00467 Promotes the Viability and Proliferation Yet Inhibits Apoptosis of Gastric Cancer Cells via Raising ITGB3 Level</text></passage><passage><infon key="fpage">109129</infon><infon key="name_0">surname:Ghafouri-Fard;given-names:S</infon><infon key="name_1">surname:Taheri;given-names:M</infon><infon key="pub-id_doi">10.1016/j.biopha.2019.109129</infon><infon key="pub-id_pmid">31326791</infon><infon key="section_type">REF</infon><infon key="source">BioMed Pharmacother</infon><infon key="type">ref</infon><infon key="volume">118</infon><infon key="year">2019</infon><offset>22649</offset><text>Maternally Expressed Gene 3 (MEG3): A Tumor Suppressor Long Non Coding RNA</text></passage><passage><infon key="fpage">e0139790</infon><infon key="issue">10</infon><infon key="name_0">surname:Zhu;given-names:J</infon><infon key="name_1">surname:Liu;given-names:S</infon><infon key="name_2">surname:Ye;given-names:F</infon><infon key="name_3">surname:Shen;given-names:Y</infon><infon key="name_4">surname:Tie;given-names:Y</infon><infon key="name_5">surname:Zhu;given-names:J</infon><infon key="pub-id_doi">10.1371/journal.pone.0139790</infon><infon key="pub-id_pmid">26444285</infon><infon key="section_type">REF</infon><infon key="source">PloS One</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2015</infon><offset>22724</offset><text>Long Noncoding RNA MEG3 Interacts With P53 Protein and Regulates Partial P53 Target Genes in Hepatoma Cells</text></passage><passage><infon key="issue">6</infon><infon key="name_0">surname:Dong;given-names:H</infon><infon key="name_1">surname:Zhang;given-names:Y</infon><infon key="name_2">surname:Xu;given-names:Y</infon><infon key="name_3">surname:Ma;given-names:R</infon><infon key="name_4">surname:Liu;given-names:L</infon><infon key="name_5">surname:Luo;given-names:C</infon><infon key="pub-id_doi">10.1093/abbs/gmz046</infon><infon key="section_type">REF</infon><infon key="source">Acta Biochim Biophys Sin (Shanghai)</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2019</infon><offset>22832</offset><text>Downregulation of Long Non-Coding RNA MEG3 Promotes Proliferation, Migration, and Invasion of Human Hepatocellular Carcinoma Cells by Upregulating TGF-beta1</text></passage><passage><infon key="elocation-id">274</infon><infon key="name_0">surname:Zuo;given-names:S</infon><infon key="name_1">surname:Wu;given-names:L</infon><infon key="name_2">surname:Wang;given-names:Y</infon><infon key="name_3">surname:Yuan;given-names:X</infon><infon key="pub-id_doi">10.3389/fonc.2020.00274</infon><infon key="pub-id_pmid">32219064</infon><infon key="section_type">REF</infon><infon key="source">Front Oncol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2020</infon><offset>22989</offset><text>Long Non-Coding RNA MEG3 Activated by Vitamin D Suppresses Glycolysis in Colorectal Cancer via Promoting C-Myc Degradation</text></passage><passage><infon key="fpage">264</infon><infon key="issue">1</infon><infon key="name_0">surname:Xu;given-names:QR</infon><infon key="name_1">surname:Tang;given-names:J</infon><infon key="name_2">surname:Liao;given-names:HY</infon><infon key="name_3">surname:Yu;given-names:BT</infon><infon key="name_4">surname:He;given-names:XY</infon><infon key="name_5">surname:Zheng;given-names:YZ</infon><infon key="pub-id_doi">10.1186/s12967-021-02907-1</infon><infon key="pub-id_pmid">34140005</infon><infon key="section_type">REF</infon><infon key="source">J Transl Med</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2021</infon><offset>23112</offset><text>Long Non-Coding RNA MEG3 Mediates the miR-149-3p/FOXP3 Axis by Reducing P53 Ubiquitination to Exert a Suppressive Effect on Regulatory T Cell Differentiation and Immune Escape in Esophageal Cancer</text></passage><passage><infon key="fpage">6723487</infon><infon key="name_0">surname:Dong;given-names:X</infon><infon key="name_1">surname:Gao;given-names:W</infon><infon key="name_2">surname:Lv;given-names:X</infon><infon key="name_3">surname:Wang;given-names:Y</infon><infon key="name_4">surname:Wu;given-names:Q</infon><infon key="name_5">surname:Yang;given-names:Z</infon><infon key="pub-id_doi">10.1155/2020/6723487</infon><infon key="pub-id_pmid">32300378</infon><infon key="section_type">REF</infon><infon key="source">Dis Markers</infon><infon key="type">ref</infon><infon key="volume">2020</infon><infon key="year">2020</infon><offset>23309</offset><text>Association Between lncRNA GAS5, MEG3, and PCAT-1 Polymorphisms and Cancer Risk: A Meta-Analysis</text></passage><passage><infon key="fpage">659</infon><infon key="issue">1</infon><infon key="name_0">surname:Zheng;given-names:Y</infon><infon key="name_1">surname:Wang;given-names:M</infon><infon key="name_2">surname:Wang;given-names:S</infon><infon key="name_3">surname:Xu;given-names:P</infon><infon key="name_4">surname:Deng;given-names:Y</infon><infon key="name_5">surname:Lin;given-names:S</infon><infon key="pub-id_doi">10.1186/s12885-020-07145-0</infon><infon key="pub-id_pmid">32669097</infon><infon key="section_type">REF</infon><infon key="source">BMC Cancer</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2020</infon><offset>23406</offset><text>LncRNA MEG3 Rs3087918 was Associated With a Decreased Breast Cancer Risk in a Chinese Population: A Case-Control Study</text></passage><passage><infon key="issue">5</infon><infon key="name_0">surname:Hou;given-names:Y</infon><infon key="name_1">surname:Zhang;given-names:B</infon><infon key="name_2">surname:Miao;given-names:L</infon><infon key="name_3">surname:Ji;given-names:Y</infon><infon key="name_4">surname:Yu;given-names:Y</infon><infon key="name_5">surname:Zhu;given-names:L</infon><infon key="pub-id_doi">10.1111/odi.13103</infon><infon key="section_type">REF</infon><infon key="source">Oral Dis</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2019</infon><offset>23525</offset><text>Association of Long Non-Coding RNA MEG3 Polymorphisms With Oral Squamous Cell Carcinoma Risk</text></passage><passage><infon key="issue">10</infon><infon key="name_0">surname:Yang;given-names:Z</infon><infon key="name_1">surname:Li;given-names:H</infon><infon key="name_2">surname:Li;given-names:J</infon><infon key="name_3">surname:Lv;given-names:X</infon><infon key="name_4">surname:Gao;given-names:M</infon><infon key="name_5">surname:Bi;given-names:Y</infon><infon key="pub-id_doi">10.1089/dna.2018.4277</infon><infon key="section_type">REF</infon><infon key="source">DNA Cell Biol</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">2018</infon><offset>23618</offset><text>Association Between Long Noncoding RNA MEG3 Polymorphisms and Lung Cancer Susceptibility in Chinese Northeast Population</text></passage><passage><infon key="issue">14</infon><infon key="name_0">surname:Cao;given-names:X</infon><infon key="name_1">surname:Zhuang;given-names:S</infon><infon key="name_2">surname:Hu;given-names:Y</infon><infon key="name_3">surname:Xi;given-names:L</infon><infon key="name_4">surname:Deng;given-names:L</infon><infon key="name_5">surname:Sheng;given-names:H</infon><infon key="pub-id_doi">10.18632/oncotarget.7764</infon><infon key="section_type">REF</infon><infon key="source">Oncotarget</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2016</infon><offset>23739</offset><text>Associations Between Polymorphisms of Long Non-Coding RNA MEG3 and Risk of Colorectal Cancer in Chinese</text></passage><passage><infon key="name_0">surname:Ghaedi;given-names:H</infon><infon key="name_1">surname:Zare;given-names:A</infon><infon key="name_2">surname:Omrani;given-names:MD</infon><infon key="name_3">surname:Doustimotlagh;given-names:AH</infon><infon key="name_4">surname:Meshkani;given-names:R</infon><infon key="name_5">surname:Alipoor;given-names:S</infon><infon key="pub-id_doi">10.1016/j.gene.2018.07.002</infon><infon key="section_type">REF</infon><infon key="source">Gene</infon><infon key="type">ref</infon><infon key="volume">675</infon><infon key="year">2018</infon><offset>23843</offset><text>Genetic Variants in Long Noncoding RNA H19 and MEG3 Confer Risk of Type 2 Diabetes in an Iranian Population</text></passage><passage><infon key="name_0">surname:Gong;given-names:J</infon><infon key="name_1">surname:Liu;given-names:W</infon><infon key="name_2">surname:Zhang;given-names:J</infon><infon key="name_3">surname:Miao;given-names:X</infon><infon key="name_4">surname:Guo;given-names:AY</infon><infon key="pub-id_doi">10.1093/nar/gku1000</infon><infon key="section_type">REF</infon><infon key="source">Nucleic Acids Res</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">2015</infon><offset>23951</offset><text>lncRNASNP: A Database of SNPs in lncRNAs and their Potential Functions in Human and Mouse</text></passage><passage><infon key="fpage">64</infon><infon key="issue">1</infon><infon key="lpage">75</infon><infon key="name_0">surname:Wetterslev;given-names:J</infon><infon key="name_1">surname:Thorlund;given-names:K</infon><infon key="name_2">surname:Brok;given-names:J</infon><infon key="name_3">surname:Gluud;given-names:C</infon><infon key="pub-id_doi">10.1016/j.jclinepi.2007.03.013</infon><infon key="pub-id_pmid">18083463</infon><infon key="section_type">REF</infon><infon key="source">J Clin Epidemiol</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2008</infon><offset>24041</offset><text>Trial Sequential Analysis may Establish When Firm Evidence Is Reached in Cumulative Meta-Analysis</text></passage><passage><infon key="elocation-id">683809</infon><infon key="name_0">surname:Shaker;given-names:O</infon><infon key="name_1">surname:Ayeldeen;given-names:G</infon><infon key="name_2">surname:Abdelhamid;given-names:A</infon><infon key="pub-id_doi">10.3389/fgene.2021.683809</infon><infon key="pub-id_pmid">34421993</infon><infon key="section_type">REF</infon><infon key="source">Front Genet</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2021</infon><offset>24139</offset><text>The Impact of Single Nucleotide Polymorphism in the Long Non-Coding MEG3 Gene on microRNA-182 and microRNA-29 Expression Levels in the Development of Breast Cancer in Egyptian Women</text></passage><passage><infon key="fpage">BSR20200305</infon><infon key="issue">11</infon><infon key="name_0">surname:Kong;given-names:X</infon><infon key="name_1">surname:Yang;given-names:S</infon><infon key="name_2">surname:Liu;given-names:C</infon><infon key="name_3">surname:Tang;given-names:H</infon><infon key="name_4">surname:Chen;given-names:Y</infon><infon key="name_5">surname:Zhang;given-names:X</infon><infon key="pub-id_doi">10.1042/BSR20200305</infon><infon key="pub-id_pmid">33119060</infon><infon key="section_type">REF</infon><infon key="source">Biosci Rep</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2020</infon><offset>24321</offset><text>Relationship Between MEG3 Gene Polymorphism and Risk of Gastric Cancer in Chinese Population With High Incidence of Gastric Cancer</text></passage><passage><infon key="issue">2</infon><infon key="name_0">surname:Xu;given-names:B</infon><infon key="name_1">surname:Zhang;given-names:M</infon><infon key="name_2">surname:Liu;given-names:C</infon><infon key="name_3">surname:Wang;given-names:C</infon><infon key="name_4">surname:You;given-names:Z</infon><infon key="name_5">surname:Wang;given-names:Y</infon><infon key="pub-id_doi">10.22037/uj.v16i7.5585</infon><infon key="section_type">REF</infon><infon key="source">Urol J</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2020</infon><offset>24452</offset><text>Association of Long Non-Coding RNA MEG3 Polymorphisms and Risk of Prostate Cancer in Chinese Han Population</text></passage><passage><infon key="fpage">49</infon><infon key="issue">1</infon><infon key="lpage">63</infon><infon key="name_0">surname:Ali;given-names:MA</infon><infon key="name_1">surname:Shaker;given-names:OG</infon><infon key="name_2">surname:Alazrak;given-names:M</infon><infon key="name_3">surname:AbdelHafez;given-names:MN</infon><infon key="name_4">surname:Khalefa;given-names:AA</infon><infon key="name_5">surname:Hemeda;given-names:NF</infon><infon key="pub-id_doi">10.3233/CBM-191072</infon><infon key="pub-id_pmid">32176630</infon><infon key="section_type">REF</infon><infon key="source">Cancer Biomark</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2020</infon><offset>24560</offset><text>Association Analyses of a Genetic Variant in Long Non-Coding RNA MEG3 With Breast Cancer Susceptibility and Serum MEG3 Expression Level in the Egyptian Population</text></passage><passage><infon key="fpage">100636</infon><infon key="name_0">surname:Mazraeh;given-names:SA</infon><infon key="name_1">surname:Gharesouran;given-names:J</infon><infon key="name_2">surname:Fard;given-names:SG</infon><infon key="name_3">surname:Ketab;given-names:FNG</infon><infon key="name_4">surname:Hosseinzadeh;given-names:H</infon><infon key="name_5">surname:Moradi;given-names:M</infon><infon key="pub-id_doi">10.1016/j.mgene.2019.100636</infon><infon key="section_type">REF</infon><infon key="source">Meta Gene</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2020</infon><offset>24723</offset><text>Association Between WT1 and MEG3 Polymorphisms and Risk of Acute Myeloid Leukemia</text></passage><passage><infon key="name_0">surname:Wei;given-names:ZM</infon><infon key="pub-id_doi">10.27690/d.cnki.ggdyk.2019.000060</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>24805</offset><text>Analysis of the Effect of Genetic Variants of MEG3-P53-MDM2-PTEN Molecular Pathway on Hepatocarcinogenesis</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Zhuo;given-names:ZJ</infon><infon key="name_1">surname:Zhang;given-names:R</infon><infon key="name_2">surname:Zhang;given-names:J</infon><infon key="name_3">surname:Zhu;given-names:J</infon><infon key="name_4">surname:Yang;given-names:T</infon><infon key="name_5">surname:Zou;given-names:Y</infon><infon key="pub-id_doi">10.18632/aging.101406</infon><infon key="section_type">REF</infon><infon key="source">Aging (Albany NY)</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2018</infon><offset>24912</offset><text>Associations Between lncRNA MEG3 Polymorphisms and Neuroblastoma Risk in Chinese Children</text></passage><passage><infon key="name_0">surname:Zhang;given-names:Q</infon><infon key="name_1">surname:Ai;given-names:L</infon><infon key="name_2">surname:Dai;given-names:YG</infon><infon key="pub-id_doi">10.7507/1007-9424.201805074</infon><infon key="section_type">REF</infon><infon key="source">Chin J Bases Clinics Gen Surg</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2018</infon><offset>25002</offset><text>Association Between Polymorphism of Long Non-Coding RNA Maternally Expressed Gene 3 and Risk of Gastric Cancer</text></passage><passage><infon key="issue">14</infon><infon key="name_0">surname:Cao;given-names:X</infon><infon key="name_1">surname:Zhuang;given-names:S</infon><infon key="name_2">surname:Hu;given-names:Y</infon><infon key="name_3">surname:Xi;given-names:L</infon><infon key="name_4">surname:Deng;given-names:L</infon><infon key="name_5">surname:Sheng;given-names:H</infon><infon key="pub-id_doi">10.18632/oncotarget.7764</infon><infon key="section_type">REF</infon><infon key="source">Oncotarget</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2016</infon><offset>25113</offset><text>Associations Between Polymorphisms of Long Non-Coding RNA MEG3 and Risk of Colorectal Cancer in Chinese</text></passage><passage><infon key="fpage">19</infon><infon key="name_0">surname:Du;given-names:P</infon><infon key="name_1">surname:Li;given-names:G</infon><infon key="name_2">surname:Zhu;given-names:J</infon><infon key="name_3">surname:Luo;given-names:Y</infon><infon key="name_4">surname:Fu;given-names:N</infon><infon key="name_5">surname:Li;given-names:Y</infon><infon key="pub-id_doi">10.1007/s12041-021-01269-3</infon><infon key="pub-id_pmid">34057148</infon><infon key="section_type">REF</infon><infon key="source">J Genet</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="year">2021</infon><offset>25217</offset><text>Association of lncRNA PRNCR1 Polymorphisms With Cancer Susceptibility: A Meta-Analysis of the Current Literature</text></passage><passage><infon key="issue">6</infon><infon key="name_0">surname:Li;given-names:HN</infon><infon key="name_1">surname:Deng;given-names:N</infon><infon key="name_2">surname:Zhao;given-names:X</infon><infon key="name_3">surname:Liu;given-names:J</infon><infon key="name_4">surname:He;given-names:T</infon><infon key="name_5">surname:Ding;given-names:XW</infon><infon key="pub-id_doi">10.1007/s10147-021-01884-1</infon><infon key="section_type">REF</infon><infon key="source">Int J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2021</infon><offset>25330</offset><text>Contributions of HOTAIR Polymorphisms to the Susceptibility of Cancer</text></passage><passage><infon key="issue">6</infon><infon key="name_0">surname:Li;given-names:N</infon><infon key="name_1">surname:Cui;given-names:Z</infon><infon key="name_2">surname:Huang;given-names:D</infon><infon key="name_3">surname:Gao;given-names:M</infon><infon key="name_4">surname:Li;given-names:S</infon><infon key="name_5">surname:Song;given-names:M</infon><infon key="pub-id_doi">10.1016/j.ygeno.2020.07.015</infon><infon key="section_type">REF</infon><infon key="source">Genomics</infon><infon key="type">ref</infon><infon key="volume">112</infon><infon key="year">2020</infon><offset>25400</offset><text>Association of LINC00673 Rs11655237 Polymorphism With Cancer Susceptibility: A Meta-Analysis Based on 23,478 Subjects</text></passage><passage><infon key="name_0">surname:Wu;given-names:X</infon><infon key="name_1">surname:Li;given-names:J</infon><infon key="name_2">surname:Ren;given-names:Y</infon><infon key="name_3">surname:Zuo;given-names:Z</infon><infon key="name_4">surname:Ni;given-names:S</infon><infon key="name_5">surname:Cai;given-names:J</infon><infon key="section_type">REF</infon><infon key="source">Am J Transl Res</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2019</infon><offset>25518</offset><text>MEG3 can Affect the Proliferation and Migration of Colorectal Cancer Cells Through Regulating miR-376/PRKD1 Axis</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Jiao;given-names:J</infon><infon key="name_1">surname:Zhang;given-names:S</infon><infon key="pub-id_doi">10.3892/mmr.2019.10515</infon><infon key="section_type">REF</infon><infon key="source">Mol Med Rep</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2019</infon><offset>25631</offset><text>Long Non-Coding RNA MEG-3 Suppresses Gastric Carcinoma Cell Growth, Invasion and Migration via EMT Regulation</text></passage><passage><infon key="issue">4</infon><infon key="name_0">surname:Dong;given-names:S</infon><infon key="name_1">surname:Ma;given-names:M</infon><infon key="name_2">surname:Li;given-names:M</infon><infon key="name_3">surname:Guo;given-names:Y</infon><infon key="name_4">surname:Zuo;given-names:X</infon><infon key="name_5">surname:Gu;given-names:X</infon><infon key="pub-id_doi">10.1016/j.ygeno.2021.04.015</infon><infon key="section_type">REF</infon><infon key="source">Genomics</infon><infon key="type">ref</infon><infon key="volume">113</infon><infon key="year">2021</infon><offset>25745</offset><text>LncRNA MEG3 Regulates Breast Cancer Proliferation and Apoptosis Through miR-141-3p/RBMS3 Axis</text></passage></document>
</collection>